Name (Synonyms) | Correlation | |
---|---|---|
drug569 | COVID-19 test, polymerase chain reaction for SARS-CoV-2 Wiki | 0.71 |
drug1499 | Ivermectin Pill Wiki | 0.71 |
drug716 | Combined ART/hydroxychloroquine Wiki | 0.71 |
drug3087 | Vitamin D 1000 IU Wiki | 0.71 |
drug572 | COVID-surgRES questionaire Wiki | 0.71 |
drug2122 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D014808 | Vitamin D Deficiency NIH | 0.27 |
D012141 | Respiratory Tract Infections NIH | 0.14 |
D003141 | Communicable Diseases NIH | 0.11 |
D007239 | Infection NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100512 | Low levels of vitamin D HPO | 0.27 |
HP:0011947 | Respiratory tract infection HPO | 0.14 |
There are 2 clinical trials
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai population. Outcomes include safety and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.
Description: Comparison of adverse event rates between treatment arms
Measure: Adverse event rates Time: after first dose until day 28 of follow upDescription: comparison of median duration for detectable SAR-CoV2 by PCR from NP swab in each arm
Measure: Efficacy for shortening duration of SAR-CoV2 detection by PCR Time: weekly after treatment until 4th weekDescription: comparison of median duration for total antibody detection in each arm
Measure: Antibody detection rates Time: weekly after treatment until 4th weekThis study is intended to address whether oral daily vitamin D supplementation reduces infection with SARS-CoV-2 in healthy young adults. The primary aim of the study is to demonstrate a reduction in 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population following 24 weeks of taking oral vitamin D supplemented at a dose of 1000 I.U. daily, versus matching placebo. The secondary aims of this study are to explore: 1. Any effect on symptomatic illness. 2. The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults. 3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time. 4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/ complementary serological method 5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.
Description: asymptomatic seroconversion for SARS-CoV-2
Measure: Seroconversion Time: 24 weeksDescription: asymptomatic seroconversion for SARS-CoV-2
Measure: Interim analysis - seropositivity at 12 weeks Time: 12 weeksDescription: Sensitivity and specificity of dried blood spot assay compared with venous blood serology
Measure: Dried Blood Spot performance Time: 24 weeksDescription: Sensitivity and specificity of salivary IgA compared with venous blood serology
Measure: Salivary IgA performance Time: 24 weeksDescription: The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.
Measure: Prevalence of SARS-CoV-2 Time: 24 weeksDescription: The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time
Measure: Change in seropositivity Time: 24 weeksDescription: The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' statusÍž ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicity
Measure: Change in seroconversion rate Time: 24 weeks